



Biocon Limited

20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/EA/2025-26/41

June 16, 2025

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - BIOCON

Dear Sir/ Madam,

Subject: Qualified Institutions Placement of equity shares of face value ₹ 5 each (“Equity Shares”) (such placement, the “Issue”) by Biocon Limited (the “Company”) under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”) and Sections 42, 23(1)(b) and 62(1)(c) of the Companies Act, 2013, as amended.

We wish to inform you that pursuant to the approval accorded by the Board of Directors of the Company (the “Board”), at its meeting held on April 23, 2025, and the shareholders of the Company, pursuant to the special resolution passed through Postal Ballot on June 04, 2025, the Fund Raising Committee (the “Committee”) has at its meeting held today i.e. Monday, June 16, 2025, inter alia, passed the following resolutions:

- Authorizing the opening of the Issue today, i.e. Monday, June 16, 2025;
- Approving the floor price for the Issue, being ₹ 340.20 per Equity Share (“Floor Price”), based on the pricing formula as prescribed under Regulation 176 of the SEBI ICDR Regulations; and
- Approving and adopting the preliminary placement document dated June 16, 2025, together with the application form in connection with the Issue.

We further wish to inform you that the Fund Raising Committee has fixed the ‘relevant date’ for the purpose of the Issue, in terms of Regulation 171 of the SEBI ICDR Regulations, as June 16, 2025, and accordingly the floor price in respect of the Issue has been determined, based on the pricing formula as prescribed under Regulation 176(1) of the SEBI ICDR Regulations, as ₹ 340.20 per Equity Share.

Pursuant to Regulation 176(1) of the SEBI ICDR Regulations, as amended and in accordance with the approval of the Shareholders accorded through a special resolution passed through Postal Ballot on June 04, 2025, the Company may at its discretion offer a discount of not more than 5% on the floor price for the Issue.



The Issue price will be determined by the Company in consultation with the Book Running Lead Managers appointed in relation to the Issue.

The meeting of the Fund Raising Committee commenced at 6:30 PM and concluded at 6:40 PM.

In relation to the qualified institutions placement, we will file the preliminary placement document with your office today.

Further, pursuant to the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Code of Conduct for Prevention of Insider Trading of the Company for regulating, monitoring and reporting of trading by insiders, the trading window for dealing in the securities of the Company has already been closed till further notice, for the purpose of the Issue.

We request you to kindly take this on records, and the same be treated as compliance under Regulation 29(1) and 30 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations Disclosure Requirements) Regulations, 2015, as amended.

Copy of this intimation is being also made available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Siddharth Mittal
Managing Director & CEO
DIN: 03230757